1|Page
NR 565 FINAL EXAM QUESTIONS AND
CORRECT ANSWERS (PRACTICE
QUESTIONS) PLUS RATIONALES 2026
Q&A | LATEST EXAM REVIEW 2026/2027
[QUESTIONS 1–100] AND ANSWERS |
DETAILED RATIONALES
Introduction
The NR 565 Final Exam is associated with advanced pharmacology coursework in graduate
nursing education. Preparing for this assessment requires more than memorizing drug names and
classifications. Students need to apply pharmacological principles to patient scenarios, evaluate
medication safety, recognize adverse effects, understand clinically important interactions, and
select appropriate monitoring and patient education strategies.
This practice question bank is designed for graduate nursing students reviewing advanced
pharmacology concepts. It covers major medication classes and prescribing considerations,
including cardiovascular therapies, endocrine medications, antimicrobials, respiratory drugs,
psychiatric treatments, pain management, and medication use in special populations. Each
multiple-choice question has four options, one best answer, and a rationale explaining the correct
choice and why the alternatives are less appropriate.
Use this material as a structured revision resource. Answer each question before reading the
rationale, record the topics you miss, and revisit the relevant course materials. Pay particular
attention to contraindications, laboratory monitoring, renal and hepatic function, drug
interactions, pregnancy considerations, and patient-specific risk factors. These original practice
questions are for study purposes; they are not an official Chamberlain examination, and neither a
particular grade nor passing on the first attempt can be guaranteed. Compare the topics with your
current course syllabus and faculty-provided learning objectives.
Content area overview
NR 565 Advanced Pharmacology Review Blueprint
Suggested distribution for practice; not an official exam weighting.
Content area Questions Key topics Weight
Pharmacology foundations 1–10 Pharmacokinetics, interactions, safety 10%
Cardiovascular 11–22 Hypertension, heart failure, anticoagulation 12%
,2|Page
Endocrine 23–32 Diabetes, thyroid, corticosteroids 10%
Antimicrobials 33–44 Antibiotics, resistance, toxicity 12%
Respiratory 45–52 Asthma, COPD, inhalers 8%
Psychiatric 53–62 Antidepressants, antipsychotics, mood stabilizers 10%
Pain and neurologic 63–72 Opioids, analgesics, seizure therapy 10%
Gastrointestinal 73–78 Reflux, ulcer treatment, antiemetics 6%
Special populations 79–86 Pregnancy, contraception, older adults 8%
Medication safety 87–100 Monitoring, reconciliation, prescribing decisions 14%
QUESTIONS 1–100
Pharmacology foundations
Q1. A patient with chronic kidney disease is prescribed a medication eliminated primarily
unchanged by the kidneys. Several weeks later, the patient develops confusion and ataxia despite
taking the prescribed dose. Which explanation is most likely?
A) Increased first-pass metabolism B) Reduced renal clearance causing drug accumulation C)
Increased protein binding accelerating elimination D) Reduced oral bioavailability caused by
kidney disease
Rationale: B is correct because reduced renal clearance can increase drug half-life and serum
concentration, producing toxicity at a standard dose. A concerns hepatic metabolism. C does not
explain accumulation of a renally eliminated drug. D concerns absorption and is not the primary
mechanism.
Q2. A patient taking warfarin begins a medication that strongly inhibits CYP2C9. The INR rises
substantially. What best explains this finding?
A) Increased renal excretion of warfarin B) Complete blockade of warfarin absorption C)
Reduced warfarin metabolism, increasing anticoagulant exposure D) Reduced pharmacodynamic
effect of warfarin
Rationale: C is correct because CYP2C9 inhibition can reduce metabolism of S-warfarin and
increase anticoagulant effect. A is not the principal pathway. B would generally reduce exposure.
D contradicts the elevated INR.
Q3. A patient develops wheezing, facial swelling, and hypotension shortly after taking a
medication. Which interpretation is most appropriate?
A) Predictable, mild dose-related toxicity B) Evidence that the medication has a narrow
therapeutic index C) A reaction that requires weeks of drug accumulation D) Possible
anaphylaxis requiring immediate emergency treatment
, 3|Page
Rationale: D is correct because airway symptoms and hypotension can indicate anaphylaxis,
which requires urgent treatment, including intramuscular epinephrine when indicated. A
describes a different type of reaction. B is unrelated to the diagnosis. C is incorrect because
anaphylaxis can develop rapidly.
Q4. A patient taking a medication with a narrow therapeutic index develops significant renal
impairment. What should the prescriber consider?
A) Monitoring is unnecessary if the dose is unchanged B) Reviewing renal dosing and increasing
monitoring for toxicity C) Doubling the dose to compensate for impaired clearance D) Changing
the administration time without further assessment
Rationale: B is correct because renal impairment can alter drug exposure and increase toxicity
risk. A ignores a significant clinical change. C may cause accumulation. D does not address the
underlying pharmacokinetic issue.
Q5. A patient crushes an extended-release tablet because swallowing pills is difficult. What is the
best response?
A) Continue crushing it and divide the dose into smaller portions B) Mix the crushed tablet into a
hot beverage C) Verify the formulation and arrange a suitable alternative if crushing is unsafe D)
Double the next dose to compensate for medication loss
Rationale: C is correct because crushing some extended-release products can cause rapid drug
release and toxicity. A and B may compromise the formulation. D creates overdose risk.
Q6. A medication has a half-life of approximately 12 hours and follows first-order elimination.
About how long does it generally take to approach steady state with regular dosing?
A) 12 hours B) 24 hours C) Approximately 48–60 hours D) 10–14 days
Rationale: C is correct because steady state is generally approached after four to five half-lives.
A and B represent only one or two half-lives. D is much longer than expected unless additional
factors prolong elimination.
Q7. A patient with low serum albumin develops adverse effects from a highly protein-bound
medication despite a total drug concentration within the usual range. Which explanation is most
plausible?
A) The free drug concentration must have decreased B) Reduced protein binding may increase
the pharmacologically active free fraction C) Low albumin always increases renal clearance
enough to prevent toxicity D) Protein binding affects absorption only
Rationale: B is correct because reduced albumin can increase the unbound fraction of some
drugs, potentially increasing pharmacological effects. A reverses the likely effect. C is not
NR 565 FINAL EXAM QUESTIONS AND
CORRECT ANSWERS (PRACTICE
QUESTIONS) PLUS RATIONALES 2026
Q&A | LATEST EXAM REVIEW 2026/2027
[QUESTIONS 1–100] AND ANSWERS |
DETAILED RATIONALES
Introduction
The NR 565 Final Exam is associated with advanced pharmacology coursework in graduate
nursing education. Preparing for this assessment requires more than memorizing drug names and
classifications. Students need to apply pharmacological principles to patient scenarios, evaluate
medication safety, recognize adverse effects, understand clinically important interactions, and
select appropriate monitoring and patient education strategies.
This practice question bank is designed for graduate nursing students reviewing advanced
pharmacology concepts. It covers major medication classes and prescribing considerations,
including cardiovascular therapies, endocrine medications, antimicrobials, respiratory drugs,
psychiatric treatments, pain management, and medication use in special populations. Each
multiple-choice question has four options, one best answer, and a rationale explaining the correct
choice and why the alternatives are less appropriate.
Use this material as a structured revision resource. Answer each question before reading the
rationale, record the topics you miss, and revisit the relevant course materials. Pay particular
attention to contraindications, laboratory monitoring, renal and hepatic function, drug
interactions, pregnancy considerations, and patient-specific risk factors. These original practice
questions are for study purposes; they are not an official Chamberlain examination, and neither a
particular grade nor passing on the first attempt can be guaranteed. Compare the topics with your
current course syllabus and faculty-provided learning objectives.
Content area overview
NR 565 Advanced Pharmacology Review Blueprint
Suggested distribution for practice; not an official exam weighting.
Content area Questions Key topics Weight
Pharmacology foundations 1–10 Pharmacokinetics, interactions, safety 10%
Cardiovascular 11–22 Hypertension, heart failure, anticoagulation 12%
,2|Page
Endocrine 23–32 Diabetes, thyroid, corticosteroids 10%
Antimicrobials 33–44 Antibiotics, resistance, toxicity 12%
Respiratory 45–52 Asthma, COPD, inhalers 8%
Psychiatric 53–62 Antidepressants, antipsychotics, mood stabilizers 10%
Pain and neurologic 63–72 Opioids, analgesics, seizure therapy 10%
Gastrointestinal 73–78 Reflux, ulcer treatment, antiemetics 6%
Special populations 79–86 Pregnancy, contraception, older adults 8%
Medication safety 87–100 Monitoring, reconciliation, prescribing decisions 14%
QUESTIONS 1–100
Pharmacology foundations
Q1. A patient with chronic kidney disease is prescribed a medication eliminated primarily
unchanged by the kidneys. Several weeks later, the patient develops confusion and ataxia despite
taking the prescribed dose. Which explanation is most likely?
A) Increased first-pass metabolism B) Reduced renal clearance causing drug accumulation C)
Increased protein binding accelerating elimination D) Reduced oral bioavailability caused by
kidney disease
Rationale: B is correct because reduced renal clearance can increase drug half-life and serum
concentration, producing toxicity at a standard dose. A concerns hepatic metabolism. C does not
explain accumulation of a renally eliminated drug. D concerns absorption and is not the primary
mechanism.
Q2. A patient taking warfarin begins a medication that strongly inhibits CYP2C9. The INR rises
substantially. What best explains this finding?
A) Increased renal excretion of warfarin B) Complete blockade of warfarin absorption C)
Reduced warfarin metabolism, increasing anticoagulant exposure D) Reduced pharmacodynamic
effect of warfarin
Rationale: C is correct because CYP2C9 inhibition can reduce metabolism of S-warfarin and
increase anticoagulant effect. A is not the principal pathway. B would generally reduce exposure.
D contradicts the elevated INR.
Q3. A patient develops wheezing, facial swelling, and hypotension shortly after taking a
medication. Which interpretation is most appropriate?
A) Predictable, mild dose-related toxicity B) Evidence that the medication has a narrow
therapeutic index C) A reaction that requires weeks of drug accumulation D) Possible
anaphylaxis requiring immediate emergency treatment
, 3|Page
Rationale: D is correct because airway symptoms and hypotension can indicate anaphylaxis,
which requires urgent treatment, including intramuscular epinephrine when indicated. A
describes a different type of reaction. B is unrelated to the diagnosis. C is incorrect because
anaphylaxis can develop rapidly.
Q4. A patient taking a medication with a narrow therapeutic index develops significant renal
impairment. What should the prescriber consider?
A) Monitoring is unnecessary if the dose is unchanged B) Reviewing renal dosing and increasing
monitoring for toxicity C) Doubling the dose to compensate for impaired clearance D) Changing
the administration time without further assessment
Rationale: B is correct because renal impairment can alter drug exposure and increase toxicity
risk. A ignores a significant clinical change. C may cause accumulation. D does not address the
underlying pharmacokinetic issue.
Q5. A patient crushes an extended-release tablet because swallowing pills is difficult. What is the
best response?
A) Continue crushing it and divide the dose into smaller portions B) Mix the crushed tablet into a
hot beverage C) Verify the formulation and arrange a suitable alternative if crushing is unsafe D)
Double the next dose to compensate for medication loss
Rationale: C is correct because crushing some extended-release products can cause rapid drug
release and toxicity. A and B may compromise the formulation. D creates overdose risk.
Q6. A medication has a half-life of approximately 12 hours and follows first-order elimination.
About how long does it generally take to approach steady state with regular dosing?
A) 12 hours B) 24 hours C) Approximately 48–60 hours D) 10–14 days
Rationale: C is correct because steady state is generally approached after four to five half-lives.
A and B represent only one or two half-lives. D is much longer than expected unless additional
factors prolong elimination.
Q7. A patient with low serum albumin develops adverse effects from a highly protein-bound
medication despite a total drug concentration within the usual range. Which explanation is most
plausible?
A) The free drug concentration must have decreased B) Reduced protein binding may increase
the pharmacologically active free fraction C) Low albumin always increases renal clearance
enough to prevent toxicity D) Protein binding affects absorption only
Rationale: B is correct because reduced albumin can increase the unbound fraction of some
drugs, potentially increasing pharmacological effects. A reverses the likely effect. C is not
